期刊文献+

2型糖尿病肾病患者肾脏预后因素分析 被引量:5

原文传递
导出
摘要 目的 为探讨影响2型糖尿病肾病(DN)患者肾脏预后的影响因素。方法 回顾性分析行肾穿刺活检并随访的153例DN患者的临床病理特征,对影响患者肾存活的多种因素进行了多因素分析。结果 153例患者中,男105例(68.6%),女48例(31.4%),年龄26~75(平均53)岁,糖尿病病程1~312(平均93)个月,共40例(26.1%)患者在随访过程中死亡,其中主要死亡原因为终末期肾病(25例,62.5%),其它原因包括心血管疾病(9例,22.5%)、脑血管疾病(4例,10%)、肿瘤(2例,5%)、甲亢(1例,25%)。1年和5年人存活率分别为93.8%和36.7%。中位肾生存时间69个月,1年和5年肾存活率分别为88.6%和13.2%。单因素分析表明,性别、糖尿病痛程、糖尿病视网膜病变、血压控制水平、体重指数、血浆胆固醇水平、尿蛋白水平、血浆白蛋白水平、KW结节为影响预后的因素;多因素回归分析显示,仅有糖尿病病程、眼底病变、尿蛋白、血压控制水平是影响2型DN患者肾生存率的独立因素。结论 糖尿病病程、眼底病变、尿蛋白、血压控制水平是影响2型DN患者肾生存率的独立因素。
出处 《中国医师杂志》 CAS 2006年第5期652-653,共2页 Journal of Chinese Physician
  • 相关文献

参考文献6

  • 1Reikes ST. Trends in end-stage renal diseas. Epidemiology, morbidity, and morality. Postgrad Med,2000,108( 1 ) :124-126.
  • 2黎磊石,刘志红.糖尿病肾病的治疗[J].中华老年多器官疾病杂志,2002,1(3):171-173. 被引量:14
  • 3Tanji N, Markowitz GS, Fu C, et al. Expression of advanced glycation end products and their cellular RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol,2000,11:1656-1666.
  • 4Noh H,Ha H,Yu MR,et al. High glucose increases inducible NO production in cultured rat mesangial cells, possible role in fibronectin production. Nephron,2002,90:78-85.
  • 5Zeuw D, Remuzzi G, Parring HH. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy:lessons from RENAAL. Kidney Int,2004,65(6) :2309-2320.
  • 6Heaf JG,Lokkegaard H,Larsen S. The relative prognosis of nodular and diffuse diabetic nephropathy. Stand J Urol Nephrol,2001,35(3) :233-238.

二级参考文献8

  • 1[1]The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993,329: 977-986.
  • 2[2]UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet, 1998,325: 837-853.
  • 3[3]Ruilope LM, Luno J. Angiotensin blockade in type 2 diabetic renal disease. Kidney Int Suppl, 2002,82:61-63.
  • 4[4]Pahor M, Psaty BM, Alderman MH, et al. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care, 2000,23:888-892.
  • 5[5]Fried LF, Qrchard TJ, Kasiske BL, et al. Effect of lipid reduction on the progression of renal diseases: a meta-analysis. Kidney Int, 2001,59:260-269.
  • 6[8]Brenner BM, Cooper ME, de Zeeuw D, et al. Effect of losartan on renal and cardiovascular outcome in patients with type 2 diabetes and nephropathy. N Engl J Med,2001,345: 861-869.
  • 7[9]Parving HH, Lehnert H, Brochner-Mortensen J, et al.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med,2001,345: 870-878.
  • 8刘志红.胰岛素抵抗在糖尿病肾病发病中的作用[J].中国实用内科杂志,2002,22(9):519-521. 被引量:24

共引文献13

同被引文献41

  • 1刘英哲,陈泽奇,张清梅,陈大舜,董克礼,叶仁群.1433例2型糖尿病及并发症临床流行病学调查[J].中国医师杂志,2005,7(5):607-609. 被引量:34
  • 2谌贻璞.代谢综合征肾损害:已知与未知[J].中华肾脏病杂志,2006,22(7):381-382. 被引量:12
  • 3李桂云,吴正治.STZ建立2型糖尿病大鼠模型的剂量探讨[J].深圳中西医结合杂志,2007,17(2):74-77. 被引量:34
  • 4孙焕,陈广,陆付耳.介绍几种诱发性糖尿病动物模型[J].中国实验方剂学杂志,2007,13(2):65-68. 被引量:29
  • 5ZEUW D, REMUZZI G, PARVING HH. Proteinuria a target for renoprotection in patients with type2 diabetic nephropathy : lessons from RENNAL [ J ]. Kidney Int, 2004, 65 (6) : 2309 - 2320.
  • 6Zhang R,Liao J,Morse S,et al.Kidney disease and the metabolic syndrome.Am J Med Sci,2005,330 (6):319-325.
  • 7Bonadonna RC,Cucinotta D,Fedele D,et al.The metabolic syndrome is a risk indicator of microvascular and macrovascalar complications in diabetes:results from Metascreen.a multicenter diabetes clinic based survey.Diabetes Care,2006,29(12):2701-2707.
  • 8Ejerblad E,Fored CM,Lindblad P,et al.Obesity and risk for chronic renal failure.J Am Soc Nephrol,2006,17(6):1695-1702.
  • 9Ng DP,Walker WH,Chia KS,et al.Scrutiny of the glutaminefructose-6-phosphate transaminase 1 (GFPT1) locus reveals conserved haplotype block structure not associated with diabetic nephropathy.Diabetes,2004,53(3):865-869.
  • 10Cooper ME,Jandeleit-Dahni KA.Lipids and diabetic renal disease.Curr Diab Rep,2005,5(6):445-448.

引证文献5

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部